Anavex Life Sciences Corp (AVXL)

[falconer66a]

Testing for seizure prophylaxis.

Seizures (Epilepsy) is not listed in Anavex's lengthy pipeline. I wonder how long it will take before Missling adds it to the pipeline and starts a trial?

Those with detailed experience and knowledge of drug-approval clinical trials are invited to render their perspectives on this, but it seems that conducting a clinical trial with blarcamesine as an anti-epileptic therapy could be problematic.

An epileptic seizure, I’m sure, could be precisely diagnosed and validated as such. There must be characteristic brain-wave dynamics that could be assessed. But there are a diverse number of epilepsy etiologies, exact causes. Some are caused by traumas (physical injuries), some by tumors, others by ischemias (brain blood clots or hemorrhages). There are other etiologies.

So, how does a Contract Research Organization (CRO) conducting a clinical trial select trial participants for a test of blarcamesine as an epilepsy therapy? Seems that Anavex would have to first target some particular pathology for which epileptic events are common.

In fact, blarcamesine’s ability to suppress, weaken, or prevent episodes of epilepsy may be discovered incidentally; as in the case with Rett syndrome. Rett syndrome girls or women taking blarcamesine are very likely to have significantly fewer or weaker episodes of epilepsy. The drug will prove efficacious for that debility. But getting approval to use it for other causes of epilepsy may take some time.